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Abstract
Alcohol consumption is largely associated with alterations in the extracellular glutamate 
concentrations in several brain reward regions. We have recently found that glutamate transporter 
1 (GLT-1) is downregulated following chronic exposure to ethanol for five weeks in alcohol-
preferring rats, and upregulation of the GLT-1 levels in nucleus accumbens and prefrontal cortex 
resulted, in part, in attenuating ethanol consumption. Cysteine glutamate antiporter (xCT) was also 
found to be downregulated after chronic ethanol exposure in P rats, and its upregulation could be 
valuable in attenuating ethanol drinking. In this study, we examined the effect of a synthetic 
compound, (R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153), on ethanol drinking and 
expression of GLT-1 and xCT in the amygdala and hippocampus of P rats. P rats were exposed to 
continuous free-choice access to water, 15% and 30% ethanol, and food for five weeks, and then 
after which they received treatments of MS-153 or vehicle for five days. The results showed that 
MS-153 treatment significantly reduced ethanol consumption in P rats. It was revealed that GLT-1 
and xCT expressions were downregulated in both the amygdala and hippocampus of ethanol-
vehicle treated rats (ethanol vehicle group) as compared to water control animals. Importantly, 
MS-153 treatment upregulated GLT-1 and xCT expression in these brain regions. These findings 
provide important role of MS-153 on these glutamate transporters for the attenuation of ethanol 
drinking behavior.
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Extracellular glutamate concentration is maintained through the uptake mechanism by 
astrocytes (Parpura and Verkhratsky, 2012). Glutamate uptake by these astrocytes occurs 
through several types of glutamate transporters [for review see (Danbolt, 2001)]. The most 
predominant transporter is glutamate transporter 1 (GLT-1, its human homolog termed 
excitatory amino acid transporter 2, EAAT2), which is responsible for clearing more than 
90% of extracellular glutamate (Danbolt, 2001, Mitani and Tanaka, 2003). The import of 
glutamate into astrocytes through GLT-1 is required for subsequent release by the cysteine 
glutamate antiporter (xCT), which is responsible for releasing glutamate in exchange for 
cystine (Warr et al., 1999, Melendez et al., 2005). This results in the regulation of synaptic 
glutamate release (Moussawi and Kalivas, 2010).
It has become increasingly apparent that glutamate neurotransmission in the nucleus 
accumbens (NAc) mediates drug-seeking behavior, and the changes in glutamate 
transmission in this brain region are assumed to mediate the switch from intermittent use of 
drugs to dependence (Gipson et al., 2014). It is noteworthy to mention that glutamatergic 
input into the NAc from other brain regions has a key role in regulating addictive behavior. 
Importantly, it is well known that the NAc receives glutamatergic afferents from the 
prefrontal cortex (PFC) (Papp et al., 2012, Stefanik et al., 2013), amygdala, particularly the 
basolateral amygdala (BLA) (Stuber et al., 2011, Papp et al., 2012), and the ventral 
hippocampus (Britt et al., 2012, Papp et al., 2012). Each of these glutamatergic projections 
has a role in addictive behavior. For instance, glutamatergic projections from the PFC to the 
NAc have been implicated in goal-directed behaviors and in executing an adaptive 
behavioral response (Gipson et al., 2014). Alternatively, activation of glutamatergic 
projections from the BLA to the NAc also promotes motivated behavioral response (Stuber 
et al., 2011). Additionally, activation of glutamatergic projections from the hippocampus 
(Hipp) promotes addiction-like behavior and relapse-like to cocaine seeking behavior (Vorel 
et al., 2001).
Amygdala has been extensively examined for its role in addiction (Di Ciano and Everitt, 
2004), anxiety, memory (particularly aversive learning), and emotional behavior (Lalumiere, 
2014). Additionally, both sensitization and drug seeking behaviors require glutamate release 
into the NAc and the source of this glutamate is from the amygdala and PFC (Kalivas et al., 
2009). Alternatively, more attention has been paid recently to the Hipp because it has an 
important role in reward learning and drug-context memory (Fuchs et al., 2005, Adcock et 
al., 2006, Hernandez-Rabaza et al., 2008, Delgado and Dickerson, 2012). The Hipp is an 
important brain region in terms of addiction and drug-context memory (Adcock et al., 2006, 
Meyers et al., 2006, Shen et al., 2006, Hernandez-Rabaza et al., 2008) and relapse to drug 
abuse (Vorel et al., 2001, Fuchs et al., 2005). Alternatively, other studies have shown that 
chronic ethanol exposure is associated with impairment of hippocampal neurogenesis 
(Herrera et al., 2003, He et al., 2005). Reduction in hippocampal neurogenesis has been 
linked to cocaine addiction (Noonan et al., 2010). It is well known that astrocytic xCT is an 
important source of glutathione that can protect against oxidative damage and 
neurodegeneration (Griffith, 1999, Bridges et al., 2012, Lewerenz et al., 2012). Additionally, 
it has been shown that glutamate excitotoxicity involves the inhibition of cystine exchange 
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and eventually neuronal cell death via oxidative stress (Murphy et al., 1989). These studies 
indirectly showed impact of chronic ethanol exposure and the role of xCT in regulating 
glutamate level in the Hipp.
Alcohol consumption is associated with alterations in the extracellular glutamate 
concentrations in various brain reward regions [reviewed by (Rao and Sari, 2012)]. 
Additionally, studies have reported increases in glutamate concentrations in ethanol 
withdrawal and binge ethanol-drinking paradigms (Dahchour and De Witte, 1999, Ward et 
al., 2009), as well as in hippocampal rat slides (Roberto et al., 2004). We have recently 
found that GLT-1 is downregulated in P rats following exposure to ethanol for five weeks in 
the NAc but not in the PFC (Sari et al., 2013). Recent studies from our laboratory have 
shown that ceftriaxone treatment in P rats, known to upregulate GLT-1 expression 
(Rothstein et al., 2005), resulted in attenuating ethanol consumption and this effect was 
associated, in part, with upregulation of GLT-1 expression in the NAc and PFC (Sari et al., 
2011) as well as in the amygdala (Rao and Sari, 2014).
In this study, we tested MS-153 [(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline] as a 
compound known to enhance glutamate uptake (Shimada et al., 1999). This compound has 
been shown to prevent release of glutamate in case of ischemia, probably by inhibiting high 
voltage-gated calcium channels via interactions with protein kinase C (PKC) (Uenishi et al., 
1999). Interestingly, MS-153 was effective in inhibiting the development of tolerance and 
physical dependence to morphine (Nakagawa et al., 2001). Additionally, the conditioned 
rewarding effects of morphine, methamphetamine and cocaine were also inhibited with 
MS-153 treatment (Nakagawa et al., 2005). Importantly, we recently reported that MS-153 
treatment (at a dose of 50 mg/kg/day i.p.) attenuated ethanol intake in P rats, and that this 
effect was associated, at least in part, with upregulation of GLT-1 expression in the NAc but 
not in the PFC. Additionally, we showed that GLT-1 upregulation, in the NAc of MS-153 
treated rats, was associated with upregulation of the nuclear NF-kB level and 
downregulation of the cytoplasmic IkBα level as a possible pathway underlying the GLT-1 
upregulatory effect of MS-153 (Alhaddad et al., 2014b). Based upon this evidence, we 
aimed in this study to examine the effects of MS-153 treatment in modulating the expression 




Male alcohol-preferring (P) rats, an established model for alcoholism (Sari et al., 2006), 
were used in this study to test the effect of MS-153 on ethanol drinking as well as the 
expressions of GLT-1 and xCT in both the amygdala and Hipp. P rats were received from 
Indiana University School of Medicine (Indianapolis, USA) at the age of 21–30 Days. In the 
Department of Laboratory Animal Resources (The University of Toledo, Health Science 
Campus), P rats were individually housed in bedded plastic tubs. All animals had ad lib 
access to food and water. P rats were accustomed to a temperature of 25°C, 50% humidity, 
and a 12-hour light-dark cycle. All experimental and animal housing procedures mentioned 
were approved by the Institutional Animal Care and Use Committee of The University of 
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Toledo in accordance with the guidelines of the Institutional Animal Care and Use 
Committee of the National Institutes of Health and the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life 
Sciences, 1996). At the beginning of this study, all animals were 90 days old. Three 
experimental groups were used. (1) The ethanol-naïve vehicle group had free access to food 
and water only (n=5) and received i.p. injections of vehicle solution (1% DMSO in PBS); 
(2) the ethanol vehicle group received i.p. injections of the same vehicle solution (n=10); 
and (3) the ethanol MS-153 group received i.p. injections of MS-153 (50 mg/kg body 
weight) (n=5). During the entire study, the last two groups (ethanol vehicle group and 
ethanol MS-153 group) had continuous free-choice access to water, 15% and 30% ethanol 
and food.
Behavioral drinking paradigms
At the age of 90 days, both the ethanol vehicle and ethanol MS-153 groups were exposed to 
uninterrupted, free-choice access to water, 15% and 30% ethanol, and food for five weeks, 
as described recently (Sari et al., 2011). During the last two weeks, we measured body 
weight, ethanol intake and water intake three times per week. Both ethanol and water intake 
were measured by subtracting the weight of the bottle containing ethanol or water from its 
initial weight. Using the densitometry formula, ethanol intake measurements were converted 
into the grams of ethanol consumed per kilogram of animal body weight per day. The 
average measurements of ethanol consumption, water intake and body weight during the last 
two weeks of the five-week drinking paradigm were used as a baseline. All animals that 
drank less than 4 g of ethanol/kg/day were excluded from the study. On week 6, both the 
ethanol naïve vehicle and ethanol vehicle groups were i.p. injected with 1% DMSO in PBS. 
However, the ethanol MS-153 group received i.p injections of MS-153 (50 mg/kg body 
weight) in 1% DMSO in PBS. All animals were i.p. injected for five consecutive days. 
Ethanol intake, water intake and body weight were measured every day on which i.p. 
injections were administered. Furthermore, all animals were euthanized and then decapitated 
24 hours after the last injection.
Brain tissue harvesting
After animals were decapitated using a guillotine, brains were immediately dissected out and 
stored at −70°C. Brain regions were then extracted, in accordance with Paxinos and Watson 
Atlas for the rat brain (Paxinos and Watson, 2007), in the cryostat machine, which was 
maintained at −20°C to keep the brain tissues frozen. Extracted brain regions were then kept 
at −70° C for Western blot analysis to examine protein expression.
Western blot analysis
Western blot was performed in the amygdala and Hipp to determine changes in GLT-1 and 
xCT expressions, as described recently (Sari et al., 2009, Sari et al., 2011, Sari et al., 2013, 
Alhaddad et al., 2014a). In brief, the amygdala and Hipp samples were homogenized using 
lysis buffer with phosphatase and protease inhibitors. Samples were quantified using Bio-
Rad quantification reagents (Bio-Rad, Hercules, CA, USA), and equal amounts of proteins 
from all the groups were loaded on either 10–20% glycine gel (Invitrogen) or Mini-
PROTEAN® Precast gels (Bio-Rad). Proteins were transferred electrophoretically onto a 
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PVDF membrane. Non-specific bands were blocked by incubating the PVDF membrane in 
blocking buffer containing non-fat dry milk in TBST (50 mM Tris HCl; 150 mM NaCl, 
pH7.4; 0.1% Tween20) for 30 minutes to 1 hr at room temperature. Subsequently, the 
membrane was incubated overnight at 4°C after adding either Guinea pig anti-GLT-1 
(Millipore; 1:5000 dilution) or rabbit anti-xCT antibody (Novus; 1:1000 dilution). The 
membranes were washed in TBST, and horseradish peroxidase labeled anti-guinea pig or 
anti-rabbit secondary antibody (1:5000 dilution) was used to detect the proteins. After 
washing the membranes, chemiluminescent substrate was used to detect the proteins 
(SuperSignal® West Pico). Kodak BioMax MR Films (Thermo Fisher Scientific) were used 
to capture the signals from HRP and a SRX-101A machine was used to develop the films. β-
tubulin was used as a loading control. Subsequently, the bands on the films were digitized 
and analyzed using the MCID system. Finally, the data were reported as GLT-1/β-tubulin or 
xCT/β-tubulin ratios.
Statistical analysis
General Linear Model (GLM) repeated measures were used to analyze the behavioral data 
related to ethanol consumption, water intake and body weight, followed by an independent t-
test to determine the daily effect of treatment. Additionally, one-way ANOVA followed by 
Newman-Keuls multiple comparisons post-hoc test was used to analyze Western blot data 
(GLT-1/β-tubulin and xCT/β-tubulin ratio) for comparisons between ethanol-naïve, ethanol 
vehicle, and ethanol MS-153 treatment groups. All statistical tests results were based on 
p<0.05 level of significance.
Results
Effects of MS-153 on ethanol consumption, water intake, total fluid intake and body weight 
of P rats
GLM repeated measures demonstrated a significant main effect of day [F (1, 5) =11.436, 
p<0.0001] and a significant day × treatment interaction [F (1, 5) =9.239, p<0.0001] of 
ethanol consumption. An independent t-test revealed a statistically significant reduction in 
ethanol consumption in MS-153-treated rats from 24 hrs after the first injection (p<0.001) 
through the end of the study (Fig. 1A). Furthermore, GLM revealed a significant main effect 
of day on water intake [F (1, 5) =3.558, p<0.01] and a significant day × treatment interaction 
[F (1, 5) =2.704, p<0.05]. An independent t-test demonstrated a significant increase in water 
intake on days1, 3 and 4 of treatment (p<0.05) (Fig. 1B). Regarding body weight, statistical 
analyses using GLM revealed a significant main effect of day [F (1,5)=3.777, p<0.01] and a 
significant day × treatment interaction[F(1,5)=3.451, p<0.01]. Independent t-test did not 
reveal any statistically significant difference in body weight between ethanol vehicle- and 
ethanol MS-153-treated groups (p>0.05) (Fig. 1C). Furthermore, statistical analysis of total 
fluid intake data demonstrated a significant main effect of day [F (1, 5) =2.837, p<0.05] and 
a non-significant day × treatment interaction [F (1, 5) =1.747, p > 0.05]. However, 
independent t-test revealed a significant increase in total fluid intake in MS-153 treated P 
rats, on days 3 and 4, as compared to vehicle treated rats (p<0.05) (Fig. 1D).
Aal-Aaboda et al. Page 5









Effect of MS-153 on GLT-1 and xCT expression in Amygdala
One-way ANOVA analysis of GLT-1 data revealed a significant difference among all 
treatment groups [F (2,12)=11.56, p=0.0016]. Additionally, Newman-Keuls multiple-
comparisons post-hoc test demonstrated a significant upregulation of GLT-1 expression in 
MS-153-treated animals compared to vehicle-treated rats (p<0.01). Alternatively, GLT-1 
expression was found significantly downregulated in the ethanol-vehicle group compared to 
the naïve-vehicle group (p<0.01) (Fig. 2).
Furthermore, one-way ANOVA analysis of Western blot data demonstrated a significant 
difference between the ethanol-naïve, ethanol vehicle and ethanol MS-15 treatment groups 
[F (2,12) =9.698, p=0.0031). Newman-Keuls multiple-comparisons post-hoc test 
demonstrated a significant upregulation of xCT expression in the MS-153-treated group 
compared to the ethanol vehicle-treated group (p<0.01). Furthermore, Newman-Keuls post-
hoc test revealed a significant downregulation of xCT expression in ethanol vehicle animals 
compared to ethanol-naïve vehicle animals (p<0.05). However, statistical analysis did not 
show any significant difference in xCT expression between ethanol-naïve vehicle- and 
MS-153-treated groups (Fig. 3).
Effect of MS-153 on GLT-1 and xCT expression in the Hippocampus
One-way ANOVA demonstrated a significant difference in GLT-1 expression among all 
treatment groups [F(2,12)=12.83, p=0.001). Further, Newman-Keuls post-hoc test revealed a 
significant upregulation of GLT-1 expression in MS-153-treated rats compared to vehicle-
treated rats (p<0.01). Additionally, GLT-1 expression was found to be significantly 
downregulated in the ethanol vehicle group as compared to the naïve vehicle group 
(p<0.05). However, no significant difference was found between naïve and MS-153 
treatment groups (Fig. 4).
We further explored the effect of MS-153 on xCT expression in the Hipp (Fig. 5). One-way 
ANOVA demonstrated a significant difference among the ethanol naïve, ethanol vehicle and 
ethanol MS-153 treatment groups [F (2,12)=7.167, p=0.009). Newman-Keuls, multiple-
comparisons, post-hoc test revealed a significant upregulation of xCT expression in the 
MS-153-treated group compared to the ethanol vehicle-treated group (p<0.01). Additionally, 
xCT was significantly downregulated in the ethanol vehicle group compared to the ethanol 
naïve vehicle group (p<0.05). Statistical analysis did not show a significant difference in 
xCT expression between the ethanol naïve vehicle and MS-153 treatment groups.
Discussion
In this study, we report that MS-153 treatment is associated with a significant attenuation in 
daily ethanol consumption starting 24 hours after the first dose of MS-153 compared to 
vehicle-treated animals. Additionally, water intake in MS-153- treated rats was found to be 
significantly higher than in vehicle-treated rats. Statistical analyses did not show any 
significant effect on body weight of the MS-153-treated animals during the study. It is 
noteworthy that water intake in the MS-153-treated group was significantly higher compared 
to control animals on days 1, 3 and 4, which could be explained as a behavioral 
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compensatory mechanism due to reduction in ethanol intake. This is in agreement with 
recent studies from our lab using ceftriaxone as a GLT-1 upregulator (Sari et al., 2011, Sari 
and Sreemantula, 2012, Rao and Sari, 2014). We also found that there is increase in total 
fluid in MS-153 treated group. This was due to increase in water intake in MS-153 treated 
group as compared to control group.
A reduction in ethanol intake was found, along with significant upregulation of xCT and 
GLT-1 expressions in the amygdala and Hipp. Elevated extracellular glutamate 
concentrations have been reported after ethanol exposure in the amygdala and Hipp 
(Dahchour and De Witte, 1999, Roberto et al., 2004, Chefer et al., 2011). We found a 
downregulation of GLT-1 in the amygdala and Hipp of ethanol vehicle-treated animals, 
which can partially explain the elevated glutamate concentrations. Furthermore, 
upregulation of GLT-1 expression following treatment with MS-153 may be associated in 
part with the reduction in ethanol intake in this drug-treated group. In this study, we also 
found significant downregulation of xCT expression in the amygdala and Hipp of P rats 
exposed to five weeks of continuous ethanol exposure compared to ethanol naïve rats. It is 
well known that the reduction in xCT expression causes a decrease in extracellular, non-
synaptic glutamate concentration, and consequently the loss of glutamatergic tone on 
presynaptic mGLU2/3 receptors, thereby causing an increase in synaptic glutamate release 
(Moran et al., 2005, Javitt et al., 2011). Moran and colleagues have found that restoring xCT 
activity by N-acetylcysteine prevented cocaine-seeking behavior (Moran et al., 2005). 
Alternatively, activating mGLU2/3 receptors was shown to be effective in attenuating cue-
induced ethanol seeking (Zhao et al., 2006). Additionally, chronic exposure to ethanol 
induced an inhibition of mGLU2/3 receptor function (Moussawi and Kalivas, 2010). It is 
noteworthy that modafinil requires xCT action to attenuate cocaine reinstatement by 
activating the mGLU2/3 receptor (Mahler et al., 2014). In our present study, we found that 
MS-153 treatment for five days caused an upregulation in xCT expression. Restoring the 
xCT level would eventually lead to a reduction in the extracellular glutamate level and 
therefore may reduce ethanol drinking.
The Hipp is an important brain region in terms of addiction and drug-context memory 
(Adcock et al., 2006, Meyers et al., 2006, Shen et al., 2006, Hernandez-Rabaza et al., 2008) 
and relapse to drug abuse (Vorel et al., 2001, Fuchs et al., 2005). Alternatively, other studies 
have shown that chronic alcohol exposure is associated with impairment of hippocampal 
neurogenesis (Herrera et al., 2003, He et al., 2005). Reduction in hippocampal neurogenesis 
has been linked to cocaine addiction (Noonan et al., 2010). It is well known that astrocytic 
xCT is an important source of glutathione that can protect against oxidative damage and 
neurodegeneration (Griffith, 1999, Bridges et al., 2012, Lewerenz et al., 2012). Additionally, 
it has been shown that glutamate excitotoxicity involves the inhibition of cystine exchange 
and eventually neuronal cell death via oxidative stress (Murphy et al., 1989). These studies 
indirectly support the idea that upregulation of xCT is important to decrease extracellular 
glutamate and possibly decrease the neuronal loss associated with chronic ethanol exposure.
Several studies have focused on the importance of the amygdala in addiction and drug 
reinforcement (Baxter and Murray, 2002, Sinclair et al., 2012, Christian et al., 2013). 
Chronic ethanol exposure was found associated with increased presynaptic glutamate release 
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(Roberto et al., 2004). Alternatively, elevated extracellular glutamate and neuronal loss were 
found associated with chronic ethanol exposure in the Hipp. These findings further support 
our suggestions regarding the downregulation of xCT. Accordingly, upregulating xCT 
expression using MS-153 might be important for targeting the elevated extracellular 
glutamate concentrations in the amygdala and consequently reducing ethanol consumption.
In summary, the present study demonstrates that MS-153 is effective in attenuating ethanol 
consumption in male P rats after challenging them with five weeks of a free-choice ethanol-
drinking paradigm. The reduction in ethanol intake was found to be associated, at least in 
part, with upregulation of both xCT and GLT-1 expression in the amygdala and Hipp. Based 
on these findings, we conclude that MS-153 is a drug target that may normalize GLT-1 and 
xCT expression and consequently reduce alcohol dependence.
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(A) Effects of MS-153 treatment on average daily ethanol intake (g/kg/day) in male P rats 
exposed to five weeks of continuous free choice of ethanol and water. Statistical analyses 
demonstrated a significant difference between MS-153 treated group (n=5) and ethanol 
vehicle group (n=10). Additionally, independent t-test revealed a significant decrease in 
ethanol intake with MS-153 (50 mg/kg, i.p.) treated group from Day 1 (24 hrs after the first 
i.p. injection) through Day 5 as compared to ethanol vehicle group. (B) Effects of MS-153 
treatment on average daily water intake (ml/kg/day) in male P rats exposed to five weeks of 
continuous free choice of ethanol and water. Statistical analysis revealed a significant 
increase in water consumption in MS-153-treated P rats as compared to ethanol vehicle-
treated P rats, on days 1, 3 and 4. (C) Effects of MS-153 treatment on body weight (grams) 
of male P rats exposed to five weeks of continuous free choice access to ethanol and water. 
Statistical analysis of animals’ body weight data revealed no significant difference in body 
weight between the ethanol MS-153-treated group and the ethanol vehicle-treated group 
during the entire period of the study. (D) Effect of MS-153 treatment on total fluid intake of 
male P rats exposed to continuous free choice access to ethanol and water. Statistical 
analysis showed significant increase in total fluid intake in MS-153 treated group, on days 3 
and 4, as compared to vehicle treated group. Data are shown as mean ± SEM. (*p<0.05; 
**p<0.01; **p<0.001).
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Effect of MS-153 on GLT-1 expression in the amygdala. Upper panel: Representative 
immunoblots of GLT-1 and β-tubulin, a loading control, in the amygdala. Lower panel: 
Quantitative analysis of the immunoblots demonstrated significant upregulation of GLT-1 in 
the MS-153-treated group (50 mg/kg, i.p.; n=5) as compared to the ethanol vehicle-treated 
group (n=5). In addition, statistical analysis revealed a significant downregulation of GLT-1 
in the ethanol vehicle group as compared to the ethanol naïve vehicle group. Data are shown 
as mean ± SEM. (**p<0.01).
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Effect of MS-153 on xCT expression in the amygdala. Upper panel: Representative 
immunoblots of xCT and β-tubulin, a loading control, in the amygdala. Lower panel: 
Quantitative analysis of the immunoblots demonstrated significant upregulation of xCT in 
the MS-153 treatment group (50 mg/kg, i.p.; n=5) as compared to the ethanol vehicle group 
(n=5). Alternatively, statistical analysis revealed a significant downregulation of xCT in the 
ethanol vehicle group as compared to the ethanol naïve vehicle group. Data are shown as 
mean ± SEM. (*p<0.05; **p<0.01).
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Effect of MS-153 on GLT-1 expression in the hippocampus. Upper panel: Representative 
immunoblots of GLT-1 and β-tubulin, a loading control, in the Hipp. Lower panel: 
Quantitative analysis of the immunoblots demonstrated significant upregulation of GLT-1 in 
the MS-153 treatment group (50 mg/kg, i.p.; n=5) as compared to the ethanol vehicle group 
(n=5). Alternatively, statistical analysis revealed a significant downregulation of GLT-1 in 
the ethanol vehicle group as compared to the ethanol naïve vehicle group. Data are shown as 
mean ± SEM. (*p<0.05; ***p<0.01).
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Effect of MS-153 on xCT expression in hippocampus. Upper panel: Representative 
immunoblots of xCT and β-tubulin, a loading control, in the Hipp. Lower panel: 
Quantitative analysis of the immunoblots demonstrated significant upregulation of xCT in 
the MS-153 treatment group (50 mg/kg, i.p.; n=5) as compared to the ethanol vehicle group 
(n=5). Alternatively, statistical analysis showed a significant downregulation of xCT in the 
ethanol vehicle group as compared to the ethanol naïve vehicle group. Data are shown as 
mean ± SEM. (*p<0.05; **p<0.01).
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